CureVac is currently developing a vaccine against the coronavirus, CV-nCoV. The biopharmaceutical company is expanding a broad integrated European production network, with experienced contract development and manufacturing organisation, in order to produce the vaccine. Marco Rau, general counsel at CureVac, says, “It gives us continued control over the process and closer involvement in production.”
CureVac will first launch the vaccine in Europe. Then, South America, Africa and Asia are among the planned markets.
Rau says, “CureVac has a very global vision, which we are also applying to the production of the coronavirus vaccine”. […] Furthermore, the company’s own production facility should be fully operational by the end of 2022.
The company frequently works with Graf von Stosch and Maiwald to file its patents.
This text is a press release from JUVE Patent. The full text version of the article can be found here: https://www.juve-patent.com/news-and-stories/legal-commentary/curevacs-road-to-the-coronavirus-vaccine/